26.11.2012 Views

Peptide-Based Drug Design

Peptide-Based Drug Design

Peptide-Based Drug Design

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

268 Otvos<br />

3. Methods<br />

The main goal of this chapter is to describe the synthesis details of complex,<br />

orthogonally protected peptide constructs. Thus, major emphasis is placed on the<br />

peptide chain assembly design and practice and the alterations from the solidphase<br />

synthesis of simple, nonmodified peptides. The technology for peptide<br />

purification and quality control is not significantly different from that of other<br />

peptides, and these methods will be just briefly described. Many chapters of<br />

this book focus on the optimization of HPLC and MALDI-MS procedures for<br />

peptide separation and analysis and illustrate the expected and/or acceptable<br />

quality control parameters.<br />

3.1. Construct Assembly<br />

The basic idea is to build the construct on an oligolysine–oligoglycine<br />

scaffold where the active peptides are attached to the side chains of the scaffold<br />

lysine amino groups (Fig. 3). The two T-helper cell epitopes are built individually<br />

during the assembly of the scaffold, while the four identical M2e fragments<br />

are synthesized simultaneously after the scaffold assembly is completed. For this<br />

strategy we need to use four different amino protecting groups.<br />

While the amino acid coupling and deprotection steps used here are standard<br />

for Fmoc-N-terminal protection-based peptide synthesis, the sheer size of the<br />

construct and the fact that for the M2e fragment four peptide side chains are built<br />

concomitantly require special considerations. To complete the coupling cycles,<br />

the resin has to be loaded with relatively low amounts of reactive amino groups,<br />

the reaction times have to be extended along with occasional double coupling<br />

and deprotection cycles. The large number of acid-labile protecting groups to<br />

be removed at the end of the synthesis requires overnight cleavage from the<br />

resin even if a �-alanine moiety is incorporated between the resin and the<br />

peptide backbone to spatially separate the growing peptide chain from the solid<br />

support.<br />

The three orthogonally removable lysine protecting groups we use here are<br />

Fmoc (9-fluorenyl methoxy carbonyl), cleavable with 20% base, preferably with<br />

20% piperidine or 3% DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) (18), Dde(1-<br />

(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl), cleavable with 2% hydrazine,<br />

and Aloc (allyloxy carbonyl), cleavable with palladium. Hydrazine also removes<br />

Fmoc, and thus it can be applied only if no Fmoc groups are present on the<br />

growing peptide chain. Acid-sensitive amino protecting groups available are<br />

Boc (tert-butyloxy carbonyl), cleavable with 90% TFA, and Mtt (4-methyltrityl),<br />

cleavable with 1% TFA. We use Boc for the protection of the N-terminal<br />

moieties of N-terminal amino acids in each peptide chain as well as at the Nterminus<br />

of the scaffold.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!